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A1. HPLC method validation  
HPLC was used for the analyses of antifungal, i.e. amorolfine HCl or terbinafine HCl, 
containing samples. HPLC assays for the two antifungals in ethanol were used to 
quantify the saturation solubilities of the drugs in different monomers and to quantify 
drug present inside the nail (following extraction), and assays in a pH 5 phosphate buffer 
solution (PBS) were used to quantify drug concentrations in drug release and 
permeation experiments. Details of the HPLC method conditions used for each drug are 
shown in Chapter 2 (Table 2.2). The HPLC method was validated for specificity, 
calibration and linearity, accuracy and precision, and limit of detection (LoD) and limit of 
quantification (LoQ), and was carried out in accordance to the School of Pharmacy’s 
standard operating procedure SOP-014 (Gill, 2014). 
A1.1 Validity parameters  
A1.1.1 Specificity 
Specificity is the ability to accurately and specifically measure the analyte of interest, 
(i.e. the antifungal drugs), in the presence of other components that may be expected to 
be present in the sample, (such as residual monomers and solvents). Specificity was 
therefore established by (i) injecting blank solutions of ethanol and pH 5 phosphate 
buffer to assess interference from the solutions used in the preparation of standards 
and/or mobile phase, and (ii) injecting ethanolic solutions of excipients present in the 
formulations with and without known quantities of drug to ensure that there was no 
interference from the formulation’s excipients. 
A1.1.2 Calibration and linearity 
Stock solutions of 200 µg/ml and 50 µg/ml were prepared by accurately weighing the 
required quantity of drug, (20mg for the 200 µg/ml solution and 5mg for the 50 µg/ml 
solution), and dissolving it in ethanol or pH 5 PBS in a 100 ml volumetric flask. 
Subsequently, standard solutions (with concentrations ranging between 0.5 to 200 
µg/ml) of the two antifungals were obtained by diluting the stock solutions with ethanol 
or pH 5 PBS where needed. These standard solutions were prepared in triplicates. 
Calibration curves were constructed by assaying the standard solutions. The linearity of 
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the HPLC detection assays was assessed by plotting the peak area against the drug 
concentration.  
A1.1.3 Accuracy and precision 
Accuracy is the level of agreement between the true value and measured value (Lindsay 
and Barnes, 2003). The accuracy of the analysis obtained for each drug (n=3) expressed 
as a percentage of the expected concentration (also known as percentage recovery), 
was determined according to Equation 1. 
Accuracy =  
Cc
Cs 
 × 100                    𝐄𝐪𝐮𝐚𝐭𝐢𝐨𝐧 𝟏 
where Cc is the calculated concentration and Cs is the expected standard concentration. 
 
Precision is the measure of the variability of a set of measurements and is usually 
expressed as a percent relative standard deviation (% RSD) (Jones, 2002), as shown in 
Equation 2. 
 
% RSD =  
SD
[Drug]
 × 100                    𝐄𝐪𝐮𝐚𝐭𝐢𝐨𝐧 𝟐 
The precision of the methods was determined by evaluating repeatability (intra-day) and 
intermediate precision (inter-day). Repeatability was determined by performing three 
repeated analysis of the same standard solution on the same day, under the same 
experimental conditions. The intermediate precision was assessed by carrying out the 
analysis on three different days. For each drug, the percentage recovery of the standard 
solutions and % RSD were determined. 
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A1.1.4 Limit of detection (LoD) and limit of quantification (LoQ) 
The LoD is the lowest concentration of an analyte in a sample that can be detected, not 
quantified. LoDs were determined based on the standard deviation of the response and 
the slope, as shown in Equation 3. 
LoD =  
3.3σ
S
                    𝐄𝐪𝐮𝐚𝐭𝐢𝐨𝐧 𝟑 
where 𝜎= the standard deviation of the response which is standard error of the predicted ‘y’ value (AUC 
response value) for each ‘x’ (concentration of standard) in the regression (which can be determined from 
the y-intercepts of regression lines), and S is the slope of the calibration curve.  
 
The LoQ is the lowest concentration of any analyte in a sample that can be determined 
with acceptable precision and accuracy. Similarly to LoD, LoQs were determined based 
on the standard deviation of the response and the slope, as shown in Equation 4. 
LoQ =  
10σ
S
                    𝐄𝐪𝐮𝐚𝐭𝐢𝐨𝐧 𝟒 
 
A1.2 Amorolfine HCl HPLC method validation 
Amorolfine HCl was easily discriminated from the solutions used in the preparation of 
the standards and the mobile phase, as well as the excipients present in UV-curable gel 
formulations during a HPLC run. The method is therefore of an acceptable specificity.  
The calibration curve of standards, prepared both in ethanol and the pH 5 PBS, were 
linear over the analysed concentration ranges, with R2 > 0.999, as shown in Fig. A1.1. The 
% RSD values calculated to determine precision were ≤ 1 in all cases as shown in Table 
A1.1, and the % recovery values calculated to determine accuracy were between 98 – 
102% in all cases as shown in Table A1.2. The method is therefore of an acceptable 
accuracy, precision and linearity over the tested concentration ranges.  
Furthermore, the LoD and LoQ values (Table A1.2) are low and therefore also 
acceptable, thus enabling quantification of the lower concentration ranges required for 
drug permeation studies.  
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Fig. A1.1 Calibration curves of amorolfine HCl HPLC assays. 
 
Table A1.1 Precision of amorolfine HCl HPLC assays.  
Ethanol standards pH 5 PBS standards 
Standard 
concentration 
(µg/ml) 
Intra-day 
% RSD 
Inter-day 
% RDS 
Standard 
concentration 
(µg/ml) 
Intra-day 
% RSD 
Inter-day 
% RDS 
0.5 0.5 0.8 0.5 0.8 1.0 
1 0.5 0.6 1 0.7 1.0 
2.5 0.7 0.6 2.5 0.9 0.9 
5 0.7 0.8 5 0.8 0.9 
10 0.9 0.8 10 0.2 0.9 
25 0.6 1.0 25 0.8 0.9 
50 0.4 0.6 50 0.6 1.0 
100 0.2 0.3 100 0.4 1.0 
200 0.4 0.3 200 0.4 0.5 
 
Table A1.2 The accuracy, LoD and LoQ of amorolfine HCl HPLC assays. 
Ethanol standards pH 5 PBS standards 
Test solution 
concentration 
(µg/ml) 
 
% Recovery 
 
LoD 
(µg/ml) 
 
LoQ 
(µg/ml) 
Test solution 
concentration 
(µg/ml) 
 
% Recovery 
 
LoD 
(µg/ml) 
 
LoQ 
(µg/ml) 
25 99.8 ± 0.6  
0.15 
 
0.45 
25 99.4 ± 0.9  
0.03 
 
0.08 50 100.3 ± 0.4 50 99.9 ± 0.1 
100 99.7 ± 0.7 100 100.5 ± 1.0 
200 100.2 ± 0.1 200 100.9 ± 1.0 
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A1.3 Terbinafine HCl HPLC method validation 
Like amorolfine HCl, terbinafine HCl was easily discriminated from the solutions used in 
the preparation of the standards and the mobile phase, as well as the excipients present 
in UV-curable gel formulations during a HPLC run. The method is therefore of an 
acceptable specificity.  
The calibration curve of standards, prepared both in ethanol and the pH 5 PBS, were 
linear over the analysed concentration ranges, with R2 > 0.999, as shown in Fig. A1.2. The 
% RSD values calculated to determine precision were ≤ 1 in all cases as shown in Table 
A1.3, and the % recovery values calculated to determine accuracy were between 98 – 
102% in all cases as shown in Table A1.4. The method is therefore also of an acceptable 
accuracy, precision and linearity over the tested concentration ranges. 
Furthermore, the LoD and LoQ values (Table A1.4) are low as required for quantifying 
the amount of drug permeated through a human nail plate. 
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Fig. A1.2 Calibration curves of terbinafine HCl HPLC standards.  
 
Table A1.3 The precision of terbinafine HCl HPLC assays. 
Ethanol standards pH 5 PBS standards 
Standard 
concentration 
(µg/ml) 
Intra-day 
% RSD 
Inter-day 
% RDS 
Standard 
concentration 
(µg/ml) 
Intra-day 
% RSD 
Inter-day 
% RDS 
0.5 0.8 0.7 0.5 0.4 0.8 
1 1.0 0.8 1 0.6 0.9 
2.5 0.9 0.7 2.5 0.6 0.8 
5 0.7 0.8 5 0.4 0.9 
10 0.4 0.9 10 0.4 0.9 
25 0.1 0.7 25 0.8 0.8 
50 0.2 0.4 50 0.3 0.9 
100 0.3 1.0 100 0.4 0.9 
200 0.5 0.3 200 0.8 0.9 
 
Table A1.4 The accuracy, LoD and LoQ of terbinafine HCl HPLC assays. 
Ethanol standards pH 5 PBS standards 
Test solution 
concentration 
(µg/ml) 
 
% Recovery 
 
LoD 
(µg/ml) 
 
LoQ 
(µg/ml) 
Test solution 
concentration 
(µg/ml) 
 
% Recovery 
 
LoD 
(µg/ml) 
 
LoQ 
(µg/ml) 
25 99.6 ± 0.9  
0.16 
 
0.48 
25 99.4 ± 1.0  
0.01 
 
0.04 50 100.6 ± 0.2 50 99.3 ± 0.9 
100 100.0 ± 0.9 100 100.7 ± 0.9 
200 100.7 ± 0.9 200 100.5 ± 0.8 
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A2. GC method validation 
GC assays for monomers, i.e. DUDMA, EMA, IBOMA and HEMA, in methanol were used 
to quantify unreacted monomers remaining in cured polymer films (following 
extraction). Details of the GC method conditions used for the monomers are shown in 
Chapter 2 (Section 2.4.6.2). A GC equipped with a FID system was selected as it has great 
sensitivity, is very robust and has been shown to accurately quantify (meth)acrylate 
monomers (Khosrou et al., 2005, Sun et al., 2010). The GC method was validated for 
specificity, calibration and linearity, accuracy and precision, and LoD and LoQ in a similar 
manner to the HPLC method validation, but for quantifying residual monomers as 
oppose to drug content (Section A1.1).  
Specificity was established by (i) injecting blank solutions of methanol to assess its 
interference, and (ii) injecting methanolic solutions of excipients present in the 
formulations, with and without known quantities of specific monomers, to ensure that 
there were no interferences between the monomers and other excipients. Each 
monomer was easily discriminated from methanol which was used in the preparation of 
the standards, as well as the other excipients present in UV-curable gel formulations 
during the GC run. The method is therefore of an acceptable specificity for the 
monomers. 
Stock solutions were prepared by accurately adding the required quantity of monomer 
(i.e. 5ml of DUDMA or 1ml of EMA, IBOMA or HEMA) and dissolving it in methanol in a 
100 ml volumetric flask. Subsequently, standard solutions (between 0.6 – 55.5 mg/ml, 
0.004 – 9.2 mg/ml, 0.005 – 9.8 mg/ml and 0.005 – 10.7 mg/ml for DUDMA, EMA, IBOMA 
and HEMA respectively) were obtained by diluting the stock solutions with methanol. 
These standard solutions were prepared in triplicates. Calibration curves were 
constructed by assaying the standard solutions. The calibration curves, accuracy and 
precision data, and LoD and LoQ values for DUDMA, EMA, IBOMA and HEMA are shown 
in Sections A2.1, A2.2, A2.3 and A2.4 respectively. 
The calibration curves for all monomers were linear over the analysed concentration 
ranges with R2 > 0.999. The % RSD values calculated to determine precision were ≤ 1 in 
all cases, and the % recovery values calculated to determine accuracy were 98 – 102% in 
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all cases. The method is therefore of an acceptable accuracy, precision and linearity over 
the tested concentration ranges for the four monomers. Furthermore, the LoD and LoQ 
values are low and therefore also acceptable, thus enabling quantification of lower 
concentration ranges which are expected. 
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A2.1 DUDMA GC method validation 
Calibration curve and linearity  
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Fig. A2.1 Calibration curve of DUDMA (n=3). 
 
Accuracy and precision  
Table A2.1 Precision of DUDMA GC assays. 
Standard 
concentration 
(mg/ml) 
Intra-day 
% RSD 
Inter-day 
% RDS 
0.6 0.6 0.6 
1.1 0.6 0.3 
2.2 0.8 0.7 
3.3 0.9 0.9 
4.4 0.9 0.7 
5.6 0.8 0.8 
11.1 0.7 0.9 
16.7 1.0 0.8 
22.2 0.7 0.5 
27.8 0.8 0.4 
55.5 0.8 0.1 
 
Table A2.2 Accuracy, LoD and LoQ of DUDMA GC assays. 
Test solution 
concentration 
(mg/ml) 
 
% Recovery 
 
LoD 
(mg/ml) 
 
LoQ 
(mg/ml) 
0.5 100.0 ± 0.9  
0.14 
 
0.43 5 98.6 ± 0.6 
25 101.0 ± 0.5 
50 101.3 ± 0.3 
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A2.2 EMA GC method validation 
Calibration curve and linearity  
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Fig. A2.2 Calibration curve of EMA (n=3). 
 
Accuracy and precision  
Table A2.3 Precision of EMA GC assays. 
Standard 
concentration 
(mg/ml) 
Intra-day 
% RSD 
Inter-day 
% RDS 
0.004 1.0 1.0 
0.01 0.6 0.4 
0.02 0.2 0.9 
0.04 0.7 0.7 
0.07 0.6 0.9 
0.1 0.5 0.6 
0.3 0.6 0.9 
0.6 0.5 0.8 
1.1 0.4 0.9 
2.3 1.0 0.9 
4.6 0.2 0.9 
9.2 0.9 0.9 
 
Table A2.4 Accuracy, LoD and LoQ of EMA GC assays. 
Test solution 
concentration 
(mg/ml) 
 
% Recovery 
 
LoD 
(µg/ml) 
 
LoQ 
(µg/ml) 
0.005 100.4 ± 0.7  
1.2 
 
3.5 0.05 101.6 ± 0.7 
0.25 99.5 ± 1.0 
0.5 101.4 ± 0.9 
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A2.3 IBOMA GC method validation 
Calibration curve and linearity  
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Fig. A2.3 Calibration curve of IBOMA (n=3). 
 
Accuracy and precision  
Table A2.5 Precision of IBOMA GC assays. 
Standard 
concentration 
(mg/ml) 
Intra-day 
% RSD 
Inter-day 
% RDS 
0.005 0.3 0.5 
0.01 0.7 0.7 
0.02 0.7 0.7 
0.04 0.4 0.6 
0.08 0.5 0.6 
0.2 1.0 0.4 
0.3 0.8 0.5 
0.6 0.9 0.4 
1.2 0.9 0.7 
2.5 0.4 0.7 
4.9 0.4 1.0 
9.8 0.3 0.2 
 
Table A2.6 Accuracy, LoD and LoQ of IBOMA GC assays. 
Test solution 
concentration 
(mg/ml) 
 
% Recovery 
 
LoD 
(µg/ml) 
 
LoQ 
(µg/ml) 
0.005 100.5 ± 0.8  
1.7 
 
5.0 0.05 99.3 ± 0.5 
0.25 98.8 ± 0.9 
0.5 101.1 ± 0.5 
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A2.4 HEMA GC method validation 
Calibration curve and linearity  
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Fig. A2.4 Calibration curve of HEMA (n=3). 
 
Accuracy and precision  
Table A2.7 Precision of HEMA GC assays. 
Standard 
concentration 
(mg/ml) 
Intra-day 
% RSD 
Inter-day 
% RDS 
0.005 0.6 0.6 
0.01 0.6 1.0 
0.02 0.8 0.8 
0.04 0.8 0.8 
0.08 0.4 0.7 
0.2 0.3 0.4 
0.3 0.2 0.4 
0.7 0.7 0.6 
1.3 0.6 0.3 
2.7 0.8 0.9 
5.4 0.5 0.3 
10.7 0.4 0.5 
 
Table A2.8 Accuracy, LoD and LoQ of HEMA GC assays. 
Test solution 
concentration 
(mg/ml) 
 
% Recovery 
 
LoD 
(µg/ml) 
 
LoQ 
(µg/ml) 
0.005 101.9 ± 0.6  
1.2 
 
3.6 0.05 99.7 ± 0.7 
0.25 101.2 ± 0.9 
0.5 98.7 ± 0.9 
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A3. The levels of residual monomers in the polymer films - 
extraction method optimisation 
Ultrasonication-assisted solvent extraction was used for determining the levels of 
residual monomers in the polymer films. To obtain a high recovery and make the 
extraction procedure efficient, the effects of different factors such as (i) the amount of 
solvent and (ii) the time of extraction on recovery were investigated using the drug-free 
and solvent-free formulation containing DUDMA, EMA and a photoinitiator. This 
formulation was prepared as described in Section 2.4.2 (Chapter 2), and immediately 
after curing and removal of the oxygen inhibition layer (as per Section 2.4.4 [Chapter 2]), 
one gram of the film was placed in a glass vial, to which the extraction solvent was 
added. Methanol was chosen as the extraction solvent as it (i) does not dissolve the 
polymer; (ii) is miscible with the monomers; and (iii) displays excellent chromatographic 
behaviour, whereby it is easily discriminated from the analyte of interest.  
A3.1 Volume of extraction solvent 
In order to study the effect of methanol volume on extraction, the volume was varied in 
the range of 1 – 6 ml at 1ml intervals, and the film and solvent mix was sonicated for up 
to 3 hours, after which the solvent was analysed by gas chromatography (as per Section 
2.4.6 [Chapter 2]) to calculate the amount of residual monomers in the polymer film. Fig. 
A3.1 shows that increasing the volume of methanol to 3 ml increased the residual 
DUDMA and EMA content in the extraction solvent; however there was no further 
increase above 3ml for both monomers. Below 3ml, the residual monomers already 
extracted hinder the extraction of further monomers, possibly due to a reduction in 
their concentration gradient. Therefore 3ml was chosen as the optimal extraction 
volume – allowing maximal extraction without diluting the amount of extracted residual 
monomers unnecessarily. 
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Fig A3.1 Mean residual DUDMA and EMA quantity ± standard deviation (n=3) in extraction solvent 
(methanol) at different volumes, following a 3 hour sonication. 
 
A3.2 Selection of extraction time 
To study the effect of extraction time, 3 ml of methanol was added to the vial containing 
1g of film. Subsequently, the mixture was sonicated for up to 3 hours, with 50µl of 
solvent withdrawn from the mixture every 20 minutes for analysis to assess the time of 
extraction on recovery. Fig. A3.2 shows that the amount of residual monomers 
(especially DUDMA) extracted increased steadily between 20 – 100 minutes, after which 
there was no further increase. Therefore, 120 minutes was selected as the optimal 
extraction time. A methanol extraction volume of 3 ml and extraction time of 2 hours 
was thus used for determining the levels of residual monomers in the polymer films 
produced by the UV-curable gels formulated.  
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Fig A3.2 Mean residual DUDMA and EMA quantity ± standard deviation (n=3) in extraction solvent (3ml of 
methanol) at different ultrasonication time intervals. 
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A4. Stability of antifungals in UV-curable gel formulations over 
time  
The drug-loaded UV-curable gel formulations were stored under accelerated stability 
testing conditions (as described in Section 2.4.3.2 [Chapter 2]) and assessed for any 
changes in their appearance over time. Photographic images were taken to visualise 
colour change due to drug degradation with time and polarised light microscopy images 
(as described in Section 3.4.5.1 [Chapter 3]) were taken to observe whether the drug 
had crystallised out of the formulation with time. Tables A4.1 and A4.2 show 
photographic images and polarised light microscopy images of the amorolfine HCl– and 
terbinafine HCl– loaded UV-curable gel formulations respectively. No colour changes 
were observed nor were drug crystals present for all formulations tested. The drug-
loaded UV curable gels were therefore stable over six months.   
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Table A4.1 Photographic and polarised light microscopy (PLM) images of amorolfine HCl–loaded gel 
formulations to assess colour change due to drug degradation and presence of drug crystals over time. It 
should be noted that the vials containing the UV-curable gel formulation also contain magnetic stirrers 
within. 
 
Formulation 
 
Image 
Time  
Day  
0 
Week  
4 
Week  
8 
Week 
12 
Week 
16 
Week 
20 
Week 
24 
DUDMA & 
EMA gel 
containing 
ethanol and 
3% w/v 
amorolfine 
HCl 
 
 
Photographic 
       
PLM 
       
DUDMA & 
IBOMA gel 
containing 
ethanol and 
3% w/v 
amorolfine 
HCl 
 
 
Photographic  
       
PLM  
       
DUDMA & 
HEMA gel 
containing 
ethanol and 
4% w/v 
amorolfine 
HCl 
 
 
Photographic  
       
PLM  
       
DUDMA & 
HEMA gel 
containing 
2% w/v 
amorolfine 
HCl 
 
 
Photographic  
       
PLM  
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Table A4.2 Photographic and polarised light microscopy (PLM) images of terbinafine HCl–loaded gel 
formulations to assess colour change due to drug degradation and presence of drug crystals over time. It 
should be noted that the vials containing the UV-curable gel formulation also contain magnetic stirrers 
within. 
 
Formulation 
 
Image 
Time  
Day  
0 
Week  
4 
Week  
8 
Week 
12 
Week 
16 
Week 
20 
Week 
24 
DUDMA & 
EMA gel 
containing 
ethanol and 
4% w/v 
terbinafine 
HCl 
 
 
Photographic 
       
PLM 
       
DUDMA & 
IBOMA gel 
containing 
ethanol and 
4% w/v 
terbinafine 
HCl 
 
 
Photographic 
       
PLM 
       
DUDMA & 
HEMA gel 
containing 
ethanol and 
6% w/v 
terbinafine 
HCl 
 
 
Photographic 
       
PLM 
       
DUDMA & 
HEMA gel 
containing 
2% w/v 
terbinafine 
HCl 
 
 
Photographic 
       
PLM 
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A5. Temperature change inside UVA nail lamp during use 
The 36 Watt Cuccio Professional UVA nail lamp (Amazon UK) was monitored for 
temperature change during use with the aid of a RS-1327 Infrared thermometer (-35⁰C - 
+500⁰C) (RS Components Ltd., UK), to determine whether it could be a potential 
contributor to affecting the polymerisation process of a gel formulation and therefore 
the characteristics of the resulting polymer film.  
To monitor the temperature change, the nail lamp was switched on and a timer started 
(set for two minutes). At time intervals, i.e. 0, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110 
and 120 seconds, the temperature of a marked point inside the lamp (where a substrate 
coated with a layer of photo-curable gel is usually placed) was measured and recorded. 
This was repeated a total of three times.  
Fig. A5.1 shows the results obtained. The temperature inside the UVA nail lamp 
increased proportionally with time, with an average temperature rise of 3.0⁰C ± 0.8⁰C 
following a 2 minute cure. This increase in temperature of the UVA nail lamp during 
curing could potentially contribute to the evaporation of volatile components in the UV-
curable gel formulations, such as ethanol or HEMA, and therefore affect the properties 
of the resulting polymer film, e.g. its mass conversion from monomer gel to polymer 
film. 
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Fig. A5.1 Temperature change inside UVA nail lamp during use. Mean and standard deviation are shown, 
n=3. 
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A6. Photographic images of UV-cured films  
The UV-cured films produced by formulations containing EMA, IBOMA or HEMA, 
with/without solvent and with/without drug were photographed and the images 
obtained are shown in Table A6.1. All the films were smooth and transparent, and 
therefore considered aesthetically acceptable and thus visually suitable as a means for 
delivering drug, in this case an antifungal, through the nail plate.  
Table A6.1 Photographic images of UV-cured films.  
 Photographic image of UV-cured 
film produced from formulations 
containing 
Excipients DUDMA Solvent Drug EMA IBOMA HEMA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Formulations 
 
 
 
 
 
 
 
 
 
 
 
DUDMA 85 % v/v : 
diluent monomer 15 % v/v 
 
None 
 
 
None 
 
 
 
 
 
 
 
Ethanol 
 
 
None 
 
 
 
 
AH 
 
 
 
 
TH 
 
 
 
 
 
 
 
NMP 
 
 
None 
 
 
 
 
AH 
 
 
 
 
TH 
 
 
 
 
 
DUDMA 75 % v/v : 
diluent monomer 25 v/v 
 
 
 
 
 
 
None 
 
 
None 
 
 
 
AH 
 
 
 
TH 
Abbreviations: AH, amorolfine HCl; TH, terbinafine HCl
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A7. Adsorption isotherms of UV-cured polymer films 
N2 adsorption isotherms for the UV-cured polymer films were obtained by an automated 
surface area analyser (Chapter 3, Section 3.4.3). Figs A7.1, A7.2, A7.3 and A7.4 show the 
adsorption isotherms of the UV-cured films produced from DUDMA & EMA containing 
gel (±drug and ± solvent), DUDMA & IBOMA containing gels (± drug and ± solvent), 
DUDMA & HEMA containing gels with a DUDMA: HEMA ratio of 85:15 % v/v (± drug & ± 
solvent), and DUDMA & HEMA containing gels with a DUDMA: HEMA ratio of 75:25 % 
v/v (± drug) respectively. These isotherms are characteristic of adsorbents which are 
macroporous (i.e. contains pores with a diameter greater than 50 nm) and with weak 
interactions with the adsorbate (Sing et al., 1985), and the total pore volume (Chapter 3, 
Section 3.5.1.2) was calculated using these isotherms from the amount of nitrogen 
adsorbed at the relative pressure of 0.98. 
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Fig. A7.1 Relative pressure vs volume adsorbed for UV-cured films produced from DUDMA & EMA, 
containing gels (± drug and ± solvent). Abbreviations: AH, amorolfine HCl; TH, terbinafine HCl; ETOH, 
ethanol. 
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Fig. A7.2 Relative pressure vs volume adsorbed for UV-cured films produced from DUDMA & IBOMA, 
containing gels (± drug and ± solvent). Abbreviations: AH, amorolfine HCl; TH, terbinafine HCl; ETOH, 
ethanol. 
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Fig. A7.3 Relative pressure vs volume adsorbed for UV-cured films produced from DUDMA & HEMA 
containing gels with a DUDMA: HEMA ratio of 85:15 % v/v (± drug & ± solvent). Abbreviations: AH, 
amorolfine HCl; TH, terbinafine HCl; ETOH, ethanol. 
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Fig. A7.4 Relative pressure vs volume adsorbed for UV-cured films produced from DUDMA & HEMA 
containing gels with a DUDMA: HEMA ratio of 75:25 % v/v (± drug). Abbreviations: AH, amorolfine HCl; TH, 
terbinafine HCl; ETOH, ethanol. 
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A8. The thermal stability of drug-loaded UV-cured films 
TGA (as per Section 3.4.8.1 [Chapter 3]) was used to determine whether the presence of 
drug in the formulations containing DUDMA & EMA, IBOMA or HEMA, with or without 
ethanol or NMP alters the resulting films thermal stability. The TGA profiles of the drug-
loaded films and their corresponding drug-free films are shown in Figs A8.1 – A8.5. It can 
be seen that the presence of drug in the formulation does not alter the film’s thermal 
stability, as the TGA profiles obtained for films with and without drug are comparable.  
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Fig. A8.1 TGA profiles of UV-cured films produced from formulation containing DUDMA: EMA (85:15 v/v) 
and ethanol ± drug. The spectra in black, red and blue are for drug-free, amorolfine HCl- and terbinafine 
HCl- loaded films respectively.  
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Fig. A8.2 TGA profiles of UV-cured films produced from formulation containing DUDMA: EMA (85:15 v/v) 
and NMP ± drug. The spectra in black, red and blue are for drug-free, amorolfine HCl- and terbinafine HCl- 
loaded films respectively.  
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Fig. A8.3 TGA profiles of UV-cured films produced from formulation containing DUDMA: IBOMA (85:15 
v/v) and ethanol ± drug. The spectra in black, red and blue are for drug-free, amorolfine HCl- and 
terbinafine HCl- loaded films respectively.  
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Fig. A8.4 TGA profiles of UV-cured films produced from formulation containing DUDMA: HEMA (85:15 v/v) 
and ethanol ± drug. The spectra in black, red and blue are for drug-free, amorolfine HCl- and terbinafine 
HCl- loaded films respectively.  
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Fig. A8.5 TGA profiles of UV-cured films produced from formulation containing DUDMA: HEMA (75:25 v/v) 
± drug. The spectra in black, red and blue are for drug-free, amorolfine HCl- and terbinafine HCl- loaded 
films respectively.  
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A9. Mass Balance for ungual drug permeation study 
Mass balances were carried out for the permeation experiments conducted in Chapter 4 
(Section 4.5.2) to ensure that most of the drug had been retrieved from the modified 
Franz diffusion cell, and therefore most of the drug remaining within the nail tissue had 
been extracted. As can be seen from Table A9.1, almost all of the drug which was 
introduced to the Franz cell had been successfully retrieved. Therefore the % of drug 
permeated across the nail and remaining in the nail at day 30 data was used for 
comparing the ungual drug permeation ability of the different formulations tested 
(Chapter 4, Section 4.6.2).  
Table A9.1 Mass balance in permeation experiment at day 30. Means ± standard deviations are shown, 
n=6. 
 
Formulation 
Percentage drug recovered 
Receptor  
(i.e. permeated) 
Nail clipping Donor (i.e. film 
remaining on the 
nail plate surface) 
Total 
Curanail 1.0 ± 0.1 1.6 ± 0.4 96.9 ± 1.4 99.5 ± 1.3 
DUDMA & EMA gel containing 
ETOH & 3% w/v AH 
1.7 ± 0.2 1.8 ± 0.9 96.4 ± 1.4 99.9 ± 1.4 
DUDMA & EMA gel containing 
ETOH & 4% w/v TH 
0.8 ± 0.1 2.6 ± 0.3 96.4 ± 1.1 99.8 ± 1.1 
DUDMA & IBOMA gel containing 
ETOH & 3% w/v AH 
2.2 ± 0.5 2.5 ± 0.8 92.4 ± 2.4 96.9 ± 2.0 
DUDMA & IBOMA gel containing 
ETOH & 4% w/v TH 
1.4 ± 0.4 2.7 ± 0.4 92.8 ± 1.3 96.9 ± 1.6 
DUDMA & HEMA gel containing 
ETOH & 4% w/v AH 
2.6 ± 0.7 3.5 ± 0.5 90.9 ± 1.8 97.0 ± 2.0 
DUDMA & HEMA gel containing 
ETOH & 6% w/v TH 
1.5 ± 0.3 3.2 ± 0.6 92.7 ± 2.0 97.4 ± 2.3 
DUDMA & HEMA gel containing 
2% w/v AH 
2.4 ± 1.1 3.4 ± 0.9 91.2 ± 2.2 97.0 ± 1.2 
DUDMA & HEMA gel containing 
2% w/v TH 
1.3 ± 0.2 2.8 ± 0.7 93.3 ± 1.7 97.4 ± 1.2 
Abbreviations: AH, amorolfine HCl; TH, terbinafine HCl; ETOH, ethanol. 
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A10. Autoclaving effect on the nail plates ability to take up solvent  
To test the efficacy of UV-curable gel formulations against T. rubrum, human nail 
clippings (fingernails) were used (Chapter 4, Section 4.5.3), and to avoid the likelihood of 
introducing contaminants into the SDA plates used for the study, the nails needed to be 
sterilised before use. The method of sterilisation chosen was autoclaving at 120⁰C for 20 
minutes. In order to determine whether this method would affect the permeation of the 
permeant into and through the nail clippings, the nail clippings ability to take up solvent 
with time after autoclaving was investigated and compared to non-autoclaved nails. Two 
solvents were chosen: (i) water, which is known to swell the nail plate, and (ii) ethyl 
acetate (Fisher Scientific, UK), which has been found to dehydrate the nail plate (Hossin, 
2015).  
 
Prior to using the fingernail clippings, they were washed with distilled water and any 
excess debris was removed. The nail clippings were then left to dry for one hour at room 
temperature. Subsequently, half the nails were kept as they were, while the other half 
were autoclaved at 120⁰C for 20 minutes. The solvent uptake property of the nail 
clippings was then measured by placing the individual autoclaved and non-autoclaved 
nails in small glass vials containing 5ml of the test solvent and ensuring that the nail was 
completely submerged. The samples were then left in a water bath maintained at 25⁰C, 
and at timed intervals, i.e. after 1, 2, 4, 8, 24, 48 and 72 hours, the nail clippings were 
removed from the vials using forceps, blotted dry with Kimwipes and re-weighed. The 
experiment was repeated in triplicates and the mass change of the nail clippings 
following immersion in a solvent was calculated using the following formula: 
 
Mass change (%) =  
nail mass after solvent immersion − nail mass before solvent immersion
nail mass before solvent immersion
× 100 
 
Fig. A10.1 shows the mean mass change (%) of autoclaved and non-autoclaved nail 
clippings with time following immersion in water or ethyl acetate. As expected, 
immersion in water caused the nail plate to swell (as indicated by the increase in mass), 
while immersion in ethyl acetate caused the nail plate to dehydrate (as indicated by the 
decreases in mass). Autoclaving the nail plate, did not affect the solvent uptake ability of 
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the nail plate with time (p>0.05), and hence it can be considered a suitable method for 
nail clipping sterilisation. 
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Fig. A10.1 Mass change (%) of autoclaved & non-autoclaved nail clippings with time following immersion 
in water or ethyl acetate. Mean and standard deviation are shown, n=3. 
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A11. Growth of T. rubrum 
The growth of a T. rubrum plug (with a diameter of 8mm) inserted in the centre of a SDA 
plate was followed over two weeks, in order to help develop an adapted disc diffusion 
method to test and compare the efficacies of different antifungal-loaded UV-cured 
polymer films (when applied on human nail clippings) against the fungus. 
A total of five SDA plates were prepared with a mycelial plug inserted in the centre. This 
was done as described in Section 4.5.3.1 and 4.5.3.2 (Chapter 4). These plates were 
incubated at 32⁰C, and at time intervals, i.e. on day 2, 3, 7, 8, 9, 11, 14 and 15, the 
longest diameter of the colony was measured using a caliper and recorded.  
Fig. A11.1 shows the growth of T. rubrum with time. Under the test conditions it took on 
average a total of 1.9 ± 0.3 days for growth to be detected, and  the culture grew an 
average of 5.8 ± 0.1 mm/day from day 2 (as determined from the linear growth region). 
From this it was decided that the culture should be allowed to grow for three days prior 
to being used for studying the efficacies of different antifungal-loaded UV-cured 
polymer films, as at this point, if growth is not detected, the plate is likely to be 
defective. Furthermore, based on the rapidity of fungal growth, it was decided that 
samples should be placed at least 20 mm from the centre of the plate to allow time for 
the drug in the UV-cured polymer film to permeate through the nail and into the agar.  
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Fig. A11.1 Growth of T. rubrum with time. Mean and standard deviation are shown, n=5. 
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A12. Determining the drug-loaded UV-curable gels maximal 
penetration enhancer concentration 
To determine the maximum concentration of penetration enhancer that could be 
incorporated into drug-loaded UV-curable DUDMA & HEMA gels containing ethanol to 
produced films with the drug remaining in the dissolved state, formulations containing 
DUDMA & HEMA (with a DUDMA to HEMA ratio of 85: 15% v/v), 3% v/v 2-hydroxy-2-
methylpropiophenone, an antifungal drug (either 4% w/v amorolfine HCl or 6% w/v 
terbinafine HCl), and a penetration enhancer (i.e. water, MPE, NMP or PEG 200) at 
concentrations of 2.5, 5, 7.5, 10 and 12.5 % v/v with corresponding ethanol 
concentrations of 22.5, 20, 17.5, 15 and 12.5 % v/v were prepared.  
These formulations were visually observed for drug crystals and cured as per Section 
2.4.4 (Chapter 2). The resulting films were observed under a polarised light microscope 
(as described in Section 3.4.5.1 [Chapter 3]) and examined using XRD (as described in 
Section 3.4.5.2 [Chapter 3]) to confirm the absence or presence of drug crystals.  
The polarised light micrographs of the amorolfine HCl-loaded and terbinafine HCl-loaded 
films with their corresponding XRD patterns can be found in Tables A12.1 and A12.2 
respectively. From both tables it can be seen that the maximum water concentration 
that can be used in the drug-loaded formulations to produce films with the drug 
remaining in the dissolved state is 10% v/v, while the maximum MPE, NMP or PEG 200 
concentration that can be used is 5% v/v, as higher concentrations produces films 
containing drug crystals.  
 
 
 
 
 
 
 
276 | P a g e  
 
Table A12.1 Polarised light micrographs and corresponding XRD patterns of amorolfine HCl-loaded UV-
cured films produced from DUDMA & HEMA gel formulations containing ethanol and water (10% or 12.5% 
v/v) or MPE, NMP or PEG 200 (5% or 7.5% v/v). 
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Table A12.2 Polarised light micrographs and corresponding XRD patterns of terbinafine HCl-loaded UV-
cured films produced from DUDMA & HEMA gel formulations containing ethanol and water (10% or 12.5% 
v/v) or MPE, NMP or PEG 200 (5% or 7.5% v/v). 
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A13. Photographic images of UV-cured films loaded with 
penetration enhancers 
The UV-cured films produced by amorolfine HCl- or terbinafine HCl- loaded DUDMA & 
HEMA gel formulations containing ethanol and water, MPE, NMP or PEG 200 were 
photographed and the images obtained are shown in Table A13.1. All the films were 
smooth and transparent, and therefore considered aesthetically acceptable and thus 
visually suitable as a means for delivering drug, in this case an antifungal, through the 
nail plate.  
 
Table A13.1 Photographic images of UV-cured films produced for drug-loaded DUDMA & HEMA gel 
formulations containing ethanol (ETOH) and water, MPE, NMP or PEG 200. 
 
 
 
Photographic images of DUDMA & 
HEMA  UV-cured films produced from 
formulations containing 
4% w/v  
amorolfine HCl 
6% w/v  
terbinafine HCl 
ETOH (15% v/v) 
& 
Water (10% v/v) 
  
ETOH (20% v/v) 
& 
MPE (5% v/v) 
  
ETOH (20% v/v) 
& 
NMP (5% v/v) 
  
ETOH (20% v/v) 
& 
PEG 200 (5% v/v) 
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A14. FT-IR spectra of UV-cured films loaded with penetration 
enhancers 
In order to determine whether the incorporation of water, MPE, NMP or PEG 200 in 
drug-loaded DUDMA & HEMA gel formulations produces any noticeable changes in the 
resulting films’ chemical makeup, the films were examined using FT-IR (as per Section 
2.4.5.2 [Chapter 2]). The FT-IR spectra of the films produced from amorolfine HCl-loaded 
and terbinafine HCl-loaded gel formulations are shown in Figs A14.1 and A14.2 
respectively. It can be seen that the incorporation of the penetration enhancers in the 
drug-loaded formulations did not produce any changes in the resulting films’ FT-IR 
spectra when compared to the FT-IR spectra of the formulations containing no 
penetration enhancer. It therefore appears that the concentration of the penetration 
enhancers in the formulations were too low to produce any noticeable changes or 
changes that could be detected by FT-IR.  
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Fig. A14.1 FT-IR spectra of UV-cured films produced from 4% w/v amorolfine HCl-loaded DUDMA & HEMA 
gel formulations containing ethanol (ETOH) and no penetration enhancer (PE), water, MPE, NMP and PEG 
200. 
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Fig. A14.2 FT-IR spectra of UV-cured films produced from 6% w/v terbinafine HCl-loaded DUDMA & HEMA 
gel formulations containing ethanol (ETOH) and no penetration enhancer (PE), water, MPE, NMP and PEG 
200. 
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A15. Thermal stability of UV-cured films loaded with penetration 
enhancers 
TGA (as per Section 3.4.8.1 [Chapter 3]) was used to determine whether the 
incorporation of water, MPE, NMP or PEG 200 in drug-loaded DUDMA & HEMA gel 
formulations alters the resulting films’ thermal stability. The TGA profiles of the films 
produced from amorolfine HCl-loaded and terbinafine HCl-loaded gel formulations are 
shown in Figs A15.1 and A15.2 respectively. It can be seen that the presence of the 
penetration enhancers in the drug-loaded formulations does not alter the films thermal 
stability, as the TGA profiles obtained for films produced from formulations containing 
the penetration enhancers are comparable to the films produced from the formulations 
containing no penetration enhancer.  
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Fig. A15.1 TGA profiles of films produced from 4% w/v amorolfine HCl-loaded UV-curable DUDMA & 
HEMA gel formulations containing ethanol (ETOH) and no penetration enhancer (PE), water, MPE, NMP 
and PEG 200. 
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Fig. A15.2 TGA profiles of films produced from 6% w/v terbinafine HCl-loaded UV-curable DUDMA & 
HEMA gel formulations containing ethanol (ETOH) and no penetration enhancer (PE), water, MPE, NMP 
and PEG 200. 
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A16. Mass Balance for ungual drug permeation study using UV gels 
containing different penetration enhancers 
Mass balances were carried out for the permeation experiments conducted in Chapter 5 
(Section 5.4.2) to ensure that most of the drug had been retrieved from the modified 
Franz diffusion cell, and therefore most of the drug remaining within the nail tissue had 
been extracted. As can be seen from Table A16.1, almost all of the drug which was 
introduced to the Franz cell had been successfully retrieved. Therefore the % of drug 
permeated across the nail and remaining in the nail at day 30 data was used for 
comparing the ungual drug permeation ability of the different formulations tested 
(Chapter 5, Section 5.5.7).  
Table A16.1 Mass balance in permeation experiment at day 30. Means ± standard deviations are shown, 
n=6. 
 
Formulation 
Percentage drug recovered 
Receptor  
(i.e. permeated) 
Nail clipping Donor (i.e. film 
remaining on the 
nail plate surface) 
Total 
4% w/v AH with ETOH (15% v/v) 
& Water (10% v/v) 
3.2 ± 0.7 7.7 ± 1.0 84.0 ± 2.5 94.9 ± 3.8 
6% w/v TH with ETOH (15% v/v) 
& Water (10% v/v) 
1.7 ± 0.3 8.1 ± 1.3 86.3 ± 3.0 96.2 ± 2.2 
4% w/v AH with ETOH (20% v/v) 
& MPE (5% v/v) 
5.4 ± 0.6 6.3 ± 1.0 83.6 ± 2.5 95.3 ± 2.6 
6% w/v TH with ETOH (20% v/v) 
& MPE (5% v/v) 
2.7 ± 0.7 8.3 ± 1.9 83.9 ± 3.7 94.9 ± 2.5 
4% w/v AH with ETOH (20% v/v) 
& NMP (5% v/v) 
3.8 ± 0.7 7.2 ± 1.0 83.9 ± 2.8 94.9 ± 2.8 
6% w/v TH with ETOH (20% v/v) 
& NMP (5% v/v) 
1.7 ± 0.2 7.6 ± 1.2 87.0 ± 1.7 96.2 ± 1.4 
4% w/v AH with ETOH (20% v/v) 
& PEG 200 (5% v/v) 
3.5 ± 0.7 6.3 ± 0.6 84.4 ± 3.3 94.3 ± 3.0 
6% w/v TH with ETOH (20% v/v) 
& PEG 200 (5% v/v) 
1.7 ± 0.4 7.8 ± 1.4 85.4 ± 2.0 94.9 ± 1.8 
Abbreviations: AH, amorolfine HCl; TH, terbinafine HCl; ETOH, ethanol; PE, penetration enhancer. 
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